Latest Breaking News On - Andres guiterrez - Page 1 : comparemela.com

The new company will advance Ayala's gamma secretase inhibitors and Advaxis' prostate cancer candidate ADXS-504, but lung cancer drug ADXS-503 will be discontinued.

United statesAndres guiterrezRoni mamlukMerck keytrudaAyala pharmaceuticalsAmerican society of clinical oncologyNew jersey based advaxisAmerican societyClinical oncologyAdvaxis chief medical officer andres guiterrez